Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
LXRX Stock Forecast 2026-2027
$1.84
Current Price
$792.28M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to LXRX Price Targets
+226.1%
To High Target of $6.00
+25.0%
To Median Target of $2.30
-45.7%
To Low Target of $1.00
LXRX Price Momentum
+7.0%
1 Week Change
+17.9%
1 Month Change
+260.8%
1 Year Change
+60.0%
Year-to-Date Change
-2.6%
From 52W High of $1.89
+283.3%
From 52W Low of $0.48
📊 TOP ANALYST CALLS
Did LXRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Lexicon Pharmaceuticals is one of their latest high-conviction picks.
Latest LXRX Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, LXRX has a bullish consensus with a median price target of $2.30 (ranging from $1.00 to $6.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $1.84, the median forecast implies a 25.0% upside. This outlook is supported by 3 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 226.1% upside. Conversely, the most conservative target is provided by Roanna Ruiz at Leerink Partners, suggesting a 45.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LXRX Analyst Ratings
3
Buy
2
Hold
0
Sell
LXRX Price Target Range
Low
$1.00
Average
$2.30
High
$6.00
Current: $1.84
Latest LXRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LXRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 23, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $6.00 |
| Mar 10, 2026 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $2.30 |
| Mar 5, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $6.00 |
| Sep 2, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Aug 7, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $1.90 |
| Jun 24, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 28, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 7, 2025 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $6.00 |
| Mar 7, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $N/A |
| Mar 7, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Mar 4, 2025 | Leerink Partners | Roanna Ruiz | Market Perform | Downgrade | $1.00 |
| Mar 3, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $N/A |
| Mar 3, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Jan 29, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $N/A |
| Jan 29, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $4.00 |
| Dec 23, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $N/A |
| Nov 25, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $N/A |
| Nov 22, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $N/A |
| Nov 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $6.00 |
| Nov 13, 2024 | Needham | Joseph Stringer | Hold | Reiterates | $N/A |
Lexicon Pharmaceuticals, Inc. (LXRX) Competitors
The following stocks are similar to Lexicon Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lexicon Pharmaceuticals, Inc. (LXRX) Financial Data
Valuation Metrics
Market Cap
$792.28M
Enterprise Value
$754.05M
P/E Ratio
N/A
PEG Ratio
-8.9x
Price/Sales
15.8x
Growth & Margins
Revenue Growth (YoY)
-79.3%
Gross Margin
+96.3%
Operating Margin
-269.1%
Net Margin
-101.1%
EPS Growth
-79.3%
Financial Health
Cash/Price Ratio
+12.3%
Current Ratio
4.9x
Debt/Equity
57.9x
ROE
-39.7%
ROA
-12.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Lexicon Pharmaceuticals, Inc. (LXRX) Business Model
About Lexicon Pharmaceuticals, Inc.
What They Do
Develops biopharmaceuticals for chronic diseases.
Business Model
The company generates revenue through the discovery, development, and commercialization of biopharmaceutical products. Its key offerings include Sotagliflozin, an oral medication for various cardiovascular conditions, and it has other promising candidates in its pipeline, such as LX9211 for diabetic neuropathic pain and LX9851 for obesity.
Additional Information
Founded in 1995 and based in The Woodlands, Texas, Lexicon Pharmaceuticals employs a genomics platform to discover new therapies. The company is actively engaged in clinical trials, including Phase 3 studies for its leading candidates, positioning itself to meet significant unmet medical needs in cardiometabolic and neurological health.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
81
CEO
Dr. Michael S. Exton Ph.D.
Country
United States
IPO Year
2000
Website
www.lexpharma.comLexicon Pharmaceuticals, Inc. (LXRX) Latest News & Analysis
Latest News
Quick Summary
New analyses from the SCORED and SOTA-P-CARDIA studies indicate sotagliflozin offers benefits to various patient subgroups, supporting its mechanism of action.
Why It Matters
Positive study results for sotagliflozin may boost its market potential and sales, influencing the stock performance of related pharmaceutical companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexicon Pharmaceuticals' stock rises following Novo Nordisk's initiation of a Phase I study for oral obesity drug LX9851, a partnered therapy.
Why It Matters
Lexicon's stock surge indicates strong investor confidence in LX9851's potential, reflecting optimism about future revenue from its partnership with NVO in obesity treatment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Novo Nordisk is developing LX9851, a first-in-class oral non-incretin treatment for obesity and related metabolic disorders.
Why It Matters
LX9851’s development by Novo Nordisk could significantly impact the obesity treatment market, potentially boosting the company’s revenue and stock value as demand grows for innovative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexicon Pharmaceuticals (Nasdaq: LXRX) will present a post hoc analysis on sotagliflozin's efficacy and safety in type 1 diabetes patients at the ATTD conference on March 12, 2026.
Why It Matters
The announcement of new clinical data on sotagliflozin's efficacy in type 1 diabetes could influence Lexicon Pharmaceuticals' stock performance and market perception, impacting investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Lexicon Pharmaceuticals, Inc. (LXRX) held its Q4 2025 earnings call, discussing financial results and company updates. Further details on performance and future outlook were provided.
Why It Matters
Lexicon Pharmaceuticals' Q4 2025 earnings reveal financial performance and strategic direction, impacting stock valuation and investor sentiment. Key insights can guide investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
1 month ago
Quick Summary
Lexicon Pharmaceuticals reported key milestones, including NDA resubmission for sotagliflozin and positive FDA meeting for pilavapadin. They raised over $100 million, strengthening their financial position.
Why It Matters
Lexicon's timely milestones and strong financial position enhance its growth potential, indicating promising drug developments and increased investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About LXRX Stock
What is Lexicon Pharmaceuticals, Inc.'s (LXRX) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Lexicon Pharmaceuticals, Inc. (LXRX) has a median price target of $2.30. The highest price target is $6.00 and the lowest is $1.00.
Is LXRX stock a good investment in 2026?
According to current analyst ratings, LXRX has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LXRX stock?
Wall Street analysts predict LXRX stock could reach $2.30 in the next 12 months. This represents a 25.0% increase from the current price of $1.84. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lexicon Pharmaceuticals, Inc.'s business model?
The company generates revenue through the discovery, development, and commercialization of biopharmaceutical products. Its key offerings include Sotagliflozin, an oral medication for various cardiovascular conditions, and it has other promising candidates in its pipeline, such as LX9211 for diabetic neuropathic pain and LX9851 for obesity.
What is the highest forecasted price for LXRX Lexicon Pharmaceuticals, Inc.?
The highest price target for LXRX is $6.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 226.1% increase from the current price of $1.84.
What is the lowest forecasted price for LXRX Lexicon Pharmaceuticals, Inc.?
The lowest price target for LXRX is $1.00 from Roanna Ruiz at Leerink Partners, which represents a -45.7% decrease from the current price of $1.84.
What is the overall LXRX consensus from analysts for Lexicon Pharmaceuticals, Inc.?
The overall analyst consensus for LXRX is bullish. Out of 10 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $2.30.
How accurate are LXRX stock price projections?
Stock price projections, including those for Lexicon Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 10:19 PM UTC